NYSE: DVA

DaVita (DVA) Stock Analysis & Forecast

Nov 13 close

$174.56+0.49 (+0.3%)

Gekko Brief

Nov 9 close

DaVita closed at $185.54 on 9 November 2026, -3% on the day. The price sits above both the 50-day ($182.69) and 200-day ($179.48) moving averages, inside a 52-week range of $101.00 to $247.49. The GekkoIndex reads 55.4, in the Neutral zone, down 0.7 points over five sessions. Gekko Fair Value is $216.85, so the price is 14.4% below it.

The next earnings report is due on 1 February 2027, 78 days away (after close). Over the last 8 reports the company beat the earnings estimate 7 times, with an average move of 12% across the report. Over the last 30 days there were 3 unusual options signals. Seasonally, the next 20 trading days from this point averaged +6.5% over the last 5 years, rising in 3 of them.

4 firms rate the stock: 2 buy, 1 hold and 1 sell, with a consensus target of $222.29. A typical daily move is about 4.3%, and a typical 20-day move about 5.6%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 9, 2026 close.

DaVita price vs fair value

$234.65$174.56Nov ’25May ’26Nov ’26
Close $174.56200-day averageGekko Fair Value $234.65

DaVita quick facts

Market cap
$10.98B
P/E ratio
13.2
Forward P/E
10
EPS, TTM
$13.21
Revenue, TTM
$14.17B
Profit margin
6.5%
Dividend yield
—
Beta
0.86
Volume
602,860 avg 902,090
1-year return
+41.2%
Typical daily move
±4.7%
Typical 20-day move
±5.6%
50-day average
$182.66
200-day average
$180.91
Next earnings
Feb 1 after close
Shares outstanding
62.90M
52-week range
$101.00$247.49

DaVita swing-trade checklist

DaVita scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $174.56 sits between the 50-day ($182.66) and 200-day ($180.91) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    63.7, Accumulation

    Reading 63.7 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    25.6% below

    Price is 25.6% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 3 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 78 days

    Next report Feb 1, 2027, 78 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +3.5% on average

    From this point in the calendar, the next 20 trading days averaged +3.5% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

DaVita stock chart and price history

DaVita closed at $174.56 on Nov 13, 2026, +41.2% over the past year, inside a 52-week range of $101.00 to $247.49.

Close50-day average200-day averageVolume
DaVita share price, past year, with 50-day and 200-day moving averages and volume$100$150$200DecJan 2026FebMarAprMayJunJulAugSepOctNov174.56

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−7.7%
3 months
−1.2%
6 months
−12.6%
1 year
+41.2%
The full DVA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DVA in Gekko

Follow DaVita through every session

Put DVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track DVA in GekkoFree for 7 days. No credit card required.

About DaVita

DaVita provides dialysis care for people living with chronic kidney failure, treating patients mainly through outpatient centers while also offering care in hospitals and in patients' homes. The company runs its own laboratories to handle routine testing for dialysis patients and other physician-ordered analyses for those with end-stage renal disease, and it is widely recognized for this combination of direct treatment and lab support.

Beyond patient care, DaVita provides administrative and management services to other outpatient dialysis facilities and runs chronic disease management programs, including risk-based and other integrated care arrangements for patients with kidney disease. Its offerings also include vascular access procedures, clinical research work, physician support services, and broader kidney care programs. Together these operations serve patients across a large network of outpatient centers in the United States and in other countries, along with acute dialysis and laboratory services delivered inside hospitals.

DaVita was founded in 1994 and is headquartered in Denver, Colorado. It previously operated under the name DaVita HealthCare Partners Inc. before adopting its current name in September 2016. Its shares are listed on the NYSE under the ticker DVA.

Listed
NYSE
Sector
Health services
Industry
Medical/Nursing services
Website
davita.com

DaVita GekkoIndex: the smart money zone

DaVita’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.7, in the Accumulation zone, up 12 points over five sessions.

010063.7Accumulation

Up 12 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying42+1.5%+2.8%+10.0%+6.2%
Accumulation (current zone)210+1.2%+2.7%+4.4%+6.2%
Neutral387−0.1%−0.1%−0.2%+3.4%
Distribution56+1.9%+2.6%+4.5%+3.4%
Selling7Too few readings yet

Average DVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the DVA price, zone by zone.Track DVA in Gekko

Is DaVita stock overvalued? Gekko Fair Value

DaVita trades 25.6% below Gekko Fair Value of $234.65, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what DaVita shares are worth, recalculated every trading day.

$234.65

Gekko Fair Value, Nov 14, 2026

25.6% Undervalued

At the end of Aug 2026 the price was 23.0% below the estimate.

Gekko Fair ValueShare price, month end
$235$175Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open DVA in Gekko

DaVita insider and Congress trading

No open-market insider purchases were filed for DaVita, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for DVA in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every DVA insider filing, plotted on the chart in Gekko.Open DVA in Gekko

Congress trades last 90 days

No trades in DVA were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for DVA, plotted on the chart in Gekko.Open DVA in Gekko

Buybacks

DaVita has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$109.5M
As a share of market cap
1.00%
Trailing four quarters
$1.63B

From company filings.

Unusual options activity last 30 days

3signals, 93% of the flagged premium in calls.

Latest: Bullish flow on Oct 30, $1.55M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds DVA.

0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

DaVita earnings: next date and track record

DaVita reports on Feb 1, 2027, after the close (78 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±12%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−8.5%Feb ’25+0.2%May ’25−8.4%Aug ’25−8.4%Oct ’25+23.2%Feb ’26+25.8%May ’26−19.3%Aug ’26+1.9%Oct ’26

Last earnings call, Oct 29, 2026 AI summary

What they said
DaVita reported solid Q3 2026 results with meaningful progress in clinical strategy and Integrated Kidney Care business demonstrating economic potential. The company achieved a 10% improvement in optimal fluid removal treatments and a 5-pound average patient weight reduction. A major strategic initiative is the national rollout of expanded HD dialyzers, with 90%+ adoption in pilots across 150 centers serving 10,000+ patients, launching network-wide in November.
Guidance
Management expects a swift network-wide transition of expanded HD dialyzers with the vast majority of eligible patients transitioned by November 2026. No material financial impact from the expanded HD rollout is expected in the near term.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 29, 2026$3.82
est $3.57
+7.0%$3.58B
est $3.52B
+1.7%+1.9%
Aug 4, 2026$4.02
est $4.01
+0.2%$3.55B
est $3.50B
+1.7%−19.3%
May 5, 2026$2.87
est $2.41
+19.1%$3.42B
est $3.36B
+1.8%+25.8%
Feb 2, 2026$3.40
est $3.24
+4.9%$3.62B
est $3.51B
+3.2%+23.2%
Oct 29, 2025$2.51
est $3.17
−20.8%$3.42B
est $3.43B
−0.2%−8.4%
Aug 5, 2025$2.95
est $2.70
+9.3%$3.38B
est $3.44B
−1.8%−8.4%
May 12, 2025$2.00
est $1.95
+2.6%$3.22B
est $3.21B
+0.5%+0.2%
Feb 13, 2025$2.24
est $2.14
+4.7%$3.29B
est $3.27B
+0.9%−8.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

DaVita stock forecast and analyst price targets

Analysts’ average 12-month price target for DaVita is $222.29, +27.3% from the last close, from 4 firms rating the stock in the last 90 days.

$222.29consensus 12-month target, +27.3% from the last close
Low $180High $287
Buy2
Hold1
Sell1

Each firm’s latest rating in the last 90 days: 4 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12UBSBuy, maintained$287+64.4%
Nov 2BarclaysHold, maintained$216+23.7%
Nov 2UBSBuy, maintained$287+64.4%
Nov 2TD CowenBuy, reiterated$228+30.6%
Oct 30Bank of America SecuritiesSell, reiterated$180+3.1%
+4.4%average 20-day move after past Accumulation readings
+3.5%average move over the next 20 trading days in the last 5 years
±4.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

DaVita seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, DaVita averaged +3.5% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−1.3%2021+4.1%2022+18.1%2023−1.1%2024−1.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.5%2 of 5
Next 10 trading days−0.1%2 of 5
Next 15 trading days+2.2%3 of 5
Next 20 trading days+3.5%2 of 5
Next 30 trading days+2.5%3 of 5

For scale, DVA’s typical 20-trading-day move in either direction is about 5.6%.

DaVita market cap and key statistics

DaVita’s market cap is $10.98B, with a P/E ratio of 13.2 and revenue of $14.17B over the last twelve months.

Valuation

Market cap
$10.98B
P/E ratio
13.2
Forward P/E
10
EPS, TTM
$13.21
Gekko Fair Value
$234.65

Trading

Volume
602,860
Avg volume, 20 days
902,090
52-week high
$247.49
52-week low
$101.00
Shares outstanding
62.90M

Financials

Revenue, TTM
$14.17B
Profit margin
6.5%
Return on equity
96.8%
Quarterly earnings growth, YoY
+66.7%

Risk and income

Beta
0.86
Typical daily move
±4.7%
Typical 20-day move
±5.6%

DaVita peers

DaVita’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
ENSGEnsign+0.3%Neutral15.6% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

DaVita stock FAQ

What is DaVita’s market cap?

DaVita’s market cap is $10.98B at the Nov 13, 2026 close of $174.56, with 62.90M shares outstanding. The shares trade on a P/E ratio of 13.2.

What is the DaVita stock forecast?

The consensus analyst 12-month price target for DaVita is $222.29, +27.3% from the last close. Of the 4 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is DaVita stock overvalued or undervalued?

On Gekko’s estimate DaVita is undervalued: the Nov 13, 2026 close of $174.56 is 25.6% below Gekko Fair Value of $234.65. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does DaVita report earnings next?

DaVita is expected to report on Feb 1, 2027, after the market closes (78 days away). Analysts expect earnings of $4.14 per share on revenue of $3.65B. DaVita beat the earnings estimate in 7 of its last 8 reports, moving 12% on average across the report.

What is DaVita’s 52-week high and low?

DaVita’s 52-week high is $247.49 and its 52-week low is $101.00; it closed at $174.56 on Nov 13, 2026, +41.2% over the past year.

Is DaVita stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in DaVita?

Gekko flagged 3 unusual options signals in DaVita over the last 30 days, with $4.60M of flagged premium in calls and $350K in puts. The latest, bullish flow, was on Oct 30, 2026 with $1.55M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See DaVita the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.